A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation.
about
Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2Identification and characterization of SSTK, a serine/threonine protein kinase essential for male fertilityDistinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cellsIdentification of Fer tyrosine kinase localized on microtubules as a platelet endothelial cell adhesion molecule-1 phosphorylating kinase in vascular endothelial cellsSalicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 MutationsA differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signalingThe protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signalingInhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs)Gas6-axl receptor signaling is regulated by glucose in vascular smooth muscle cellsMolecular mechanism for a role of SHP2 in epidermal growth factor receptor signalingInhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.Expression of Gab1 lacking the pleckstrin homology domain is associated with neoplastic progression.Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty.Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophyGenetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals.Ras-related signaling pathways in valve development: ebb and flow.Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.Diverse injurious stimuli reduce protein tyrosine phosphatase-μ expression and enhance epidermal growth factor receptor signaling in human airway epithelia.Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradationAcquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.High NaCl-induced inhibition of PTG contributes to activation of NFAT5 through attenuation of the negative effect of SHP-1.Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.Intermolecular interactions of Sprouty proteins and their implications in development and disease.PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression.Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling.Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.Consequences of direct versus indirect activation of epidermal growth factor receptor in intestinal epithelial cells are dictated by protein-tyrosine phosphatase 1B.Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates.The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH(2)-terminal kinase.Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3.
P2860
Q24291169-EA47A94C-FE47-4EEC-879B-CAE1BBBB92BDQ24301417-3FAB05AD-4552-4C8B-BD6D-F5C1CA79867DQ24303794-9BCE9CE1-E2DB-428F-A0F1-9B99C4440D7AQ24322702-1DEAA89A-A760-4826-A876-A0F281BBE1FCQ27659942-02F0F618-CE6E-49DA-BE7B-D6799308F879Q27676674-BDFCA728-AE18-4959-9E2A-E5277CEC87F2Q28139198-7CFE9F30-3317-48F6-AD85-92C019811AF0Q28144437-BEBB91EA-D722-4AE5-89B3-FA54D276AF46Q28144746-95C7D7E7-E522-47AC-9748-B3514CA7EA87Q28576589-38C8DE6E-6818-4080-BFDF-2C69FBBA7D3AQ28609932-A72AA807-F586-4189-AB0F-86704AF01233Q33357659-2A14034B-F93D-4490-B1A2-EF0C6663745CQ33931319-77740938-73FC-4095-AC2E-44286A71B7A3Q34012464-EE569A26-FD27-4679-B452-82000D76488EQ34307028-2EDF7D10-B4C4-4E34-A11C-7A9151D00086Q34399676-5ECD328C-002C-4989-A3AE-3C20795EFD2FQ34979243-C052E7DE-5A83-45A8-A511-6E42BB8DBD78Q35546847-78668A02-ECC5-43C7-BA8C-F5684E0E2995Q35554092-CF3C6FC7-740B-4A41-B607-1BBF898E1BC4Q36313076-825238FE-1732-49DA-B1D4-E2E56C97287DQ36340315-8F99DAAF-C652-466B-9BD9-EB8226270102Q36578001-2E607C75-CF4A-4666-9430-8BABC2D90B29Q36734746-AEB27389-D98E-42E6-8DEE-C9F00E68B723Q36836455-69B25D1D-19F1-4B1B-B8C8-7A3BFE75C426Q36842350-CC47C85B-BEEF-48D0-BBBE-63845E2EE471Q36910173-B84EC723-C272-41E9-A686-723969B40BD2Q37093647-DAFB93ED-6214-4F67-8E2D-E48F79220FEFQ37169498-48FC92E0-E1B4-4D38-8A82-123B8799A376Q37308589-B7BAFACC-C543-4D80-8E06-485EAC4E4C6FQ37402776-A80D7F5D-2516-4675-9B79-375D0CF25A88Q37698905-1E40ABC2-D0B9-42B9-B436-9E8D668BBF02Q38167994-7B64246A-E448-4A5A-9F3E-CB6256D83486Q38261370-F044AAE6-FCBB-477D-82F9-B296B7CE99BAQ38899532-BBB0F263-9321-405F-BFA7-708CFEF39082Q40163127-21EED18B-EC60-4B57-8C63-770808AD658AQ40605597-CB848DE2-E343-4A48-A695-B2AE39FC7BDAQ40627919-231FAAFA-5761-4462-8B12-7FD778D989FEQ40775807-18E485B0-243F-4164-84BC-EE2ED39B0C3CQ40900484-7B35A86B-0D05-47AF-97B2-79A024F3D12AQ42800448-91AAEF2F-561F-4918-A8C0-7CE1CD18EA00
P2860
A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
A common requirement for the c ...... no-terminal kinase activation.
@en
A common requirement for the c ...... no-terminal kinase activation.
@nl
type
label
A common requirement for the c ...... no-terminal kinase activation.
@en
A common requirement for the c ...... no-terminal kinase activation.
@nl
prefLabel
A common requirement for the c ...... no-terminal kinase activation.
@en
A common requirement for the c ...... no-terminal kinase activation.
@nl
P2093
P2860
P356
P1476
A common requirement for the c ...... no-terminal kinase activation.
@en
P2093
Johnson GR
Salomon DS
Thompson SA
P2860
P304
16643-16646
P356
10.1074/JBC.273.27.16643
P407
P577
1998-07-01T00:00:00Z